Genocea Biosciences, Inc. (NASDAQ:GNCA)‘s stock had its “overweight” rating reiterated by stock analysts at Piper Jaffray Companies in a note issued to investors on Tuesday. They presently have a $18.00 price target on the biotechnology company’s stock, up from their previous price target of $17.00. Piper Jaffray Companies’ price target would indicate a potential upside of 208.75% from the company’s current price.

GNCA has been the topic of a number of other reports. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a report on Tuesday, May 16th. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday. Finally, ValuEngine raised shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $16.52.

Shares of Genocea Biosciences (GNCA) traded up 9.5489% during trading on Tuesday, hitting $6.3867. 3,940,918 shares of the stock traded hands. Genocea Biosciences has a 1-year low of $3.28 and a 1-year high of $7.29. The stock has a 50 day moving average price of $5.34 and a 200-day moving average price of $5.43. The stock’s market cap is $182.03 million.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.06. Equities analysts forecast that Genocea Biosciences will post ($1.89) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Genocea Biosciences, Inc. (GNCA) Receives “Overweight” Rating from Piper Jaffray Companies” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/25/genocea-biosciences-inc-gnca-receives-overweight-rating-from-piper-jaffray-companies.html.

In related news, CFO Jonathan Poole sold 45,000 shares of the business’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $6.00, for a total value of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at approximately $505,482. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.70% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in GNCA. Geode Capital Management LLC boosted its stake in shares of Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the biotechnology company’s stock worth $1,060,000 after buying an additional 1,743 shares in the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of Genocea Biosciences by 0.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 225,569 shares of the biotechnology company’s stock worth $929,000 after buying an additional 1,798 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Genocea Biosciences during the first quarter worth about $103,000. Finally, FMR LLC boosted its stake in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after buying an additional 18,574 shares in the last quarter. Institutional investors and hedge funds own 54.23% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.